QUOTE AND NEWS
BusinessWeek  Feb 2  Comment 
Forest Laboratories Inc.’s antidepressant Lexapro may help stroke patients recover some of their mental skills, a study said.
Bloomberg  Feb 1  Comment 
Forest Laboratories Inc.’s antidepressant Lexapro may help stroke patients recover some of their mental skills, a study said.
PR Newswire  Jan 25  Comment 
WALTHAM, Mass., Jan. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a fibromyalgia drug that improves sleep quality more than Pfizer's Lyrica would
Reuters  Jan 24  Comment 
Shares of Forest Laboratories Inc are inexpensive and shareholders are overlooking potential good news about the drugmaker's upcoming products and funds for making drug acquisitions, Barron's newsmagazine reported on Sunday.
Stock Blog Hub  Jan 23  Comment 
Recently, Forest Laboratories (FRX) and Spain based Almirall announced positive phase III top-line results of Forest’s pipeline candidate aclidinium, a multi dose dry-powder inhaler for the treatment of chronic obstructive pulmonary disease...
Stock Blog Hub  Jan 19  Comment 
This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 97 cents for the third quarter of fiscal 2010, well above the Zacks Consensus Estimate of 86 cents. Total revenues increased 6.7% to $1.06 billion with product revenues...
StreetInsider.com  Jan 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Forest+Labs+%28FRX%29+Reports+Mixed+Q3+Results/5254889.html for the full story.
Business Wire  Jan 19  Comment 
Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share included two one-time
BusinessWeek  Jan 14  Comment 
Armed with fresh medical insights, drug companies are redoubling their efforts to address the disease's complex causes
PR Newswire  Jan 11  Comment 
CHICAGO, Jan. 11 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide. The Seven Summits Strategic Investments Stocks To Watch Guide (go to: http://www.iotogo.com/StocksToWatch) provides investors with essential



Thank you for your suggestion
 

Forest Laboratories, Inc. (NYSE: FRX) makes branded and generic prescription drugs. Two drugs accounted for 90% of Forest's total sales and 82% of total revenue in fiscal 2008: Lexapro (66% of sales) a drug for the treatment of depression, and Namenda (24% of sales) a drug for the treatment of Alzheimer's disease.[1][2][1] The patents for both drugs will expire by 2013.[1], meaning FRX has only a few years to replace the revenue generated by these two products.

New products in Forest Laboratories' pipeline include ceftaroline, an injectable antibiotic acquired through the acquisition of Cerexa, Inc. in 2007; linaclotide, a product for the treatment of gastrointestinal disorders developed through a 50/50 co-development and marketing parntnership with Ironwood Pharmaceuticals, Inc.; and aclidinium, a drug for treating respiratory diseases to which Forest has acquired exclusive United States marketing rights through a collaborative agreement with Laboratorios Almirall SA of Spain.[1]

Company Overview

Forest Laboratories' Revenue and Net Income Over Fiscal Years 2006, 2007, and 2008 with profit margin overlaid in yellow.  (Click to enlarge.)
Forest Laboratories' Revenue and Net Income Over Fiscal Years 2006, 2007, and 2008 with profit margin overlaid in yellow. (Click to enlarge.)

Forest Laboratories revenues come primarily from the sales of branded products Lexapro and Namenda, as well as various other branded and generic drugs and several over-the-counter products.[1]

Business and Financial Metrics

Over the past three years, Forest Laboratories' revenues and net income have fluctuated. In 2006, Forest posted revenues of $2.96 billion (a 6% decline from their 2005 figure of $3.16 billion) and a net income of $709 million (a 16% decline from their 2005 net income of $839 million). While revenue grew significantly in 2007 – a 16% increase to a total of $3.44 billion – a one-time R&D charge of $476 million related to the acquisition of Cerexa, Inc. saw net income fall 36% to $454 million. Fiscal year 2008 saw the company's revenue growing 11.5% to $3.84 billion and net income improving 113% to $968 million.[2][3]

Business Segments

Sales (91% of Revenue)

Virtually all of Forest Laboratories' revenue comes from the sales of their pharmaceutical products. In 2006, sales accounted for 94% of total revenues.[2] Fiscal 2007 and 2008 saw that figure drop to 92.5% and 91%, respectively.[2] This slight drop in revenue share was more the result of increased revenue from other sources, as raw sales figures steadily increased in both 2007 and 2008.[2] In fiscal 2008, those sales broke down as follows:

  • Lexapro (66% of sales, 60% of total revenues): Lexapro (escitalopram oxalate) is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety that was approved by the FDA in 2002 (see Antidepressant Drug Market).[1] It is derived from the same parent compound (citalopram) as Celexa, an older SSRI developed by Forest Laboratories, but is more potent, according to the company.[1] The drug was responsible for 66% and 67% of total sales in 2007 and 2006, respectively. In fiscal 2008, sales of Lexapro accounted for $2.29 billion, or 60% of total revenues.[1][2]
  • Namenda (24% of sales, 22% of total revenues): Namenda (memantine HCl) is a blocker of NMDA glutamate receptors used in the treatment of Alzheimer's disease.[1] The drug is the first approved by the FDA for the treatment of moderate-to-late stage Alzheimer's disease.[1][4] The drug accounted for 21% and 18% of sales in 2007 and 2006, respectively. In fiscal 2008, sales of Namenda accounted for $830 million, or 22% of total revenues.[1][2]
  • Other (10% of sales, 9% of total revenues): The remaining 10% of Forest's sales come from their other pharmaceutical products including Campral (for the maintenance of abstinence from alcohol in patients with alcohol dependence) and Bystolic (for hypertension) in addition to their generic line of drugs and over-the-counter products.[1]

Contract Revenue (6% of Revenue)

Forest's contract revenue comes primarily from a co-promotion agreement with Daiichi Sankyo (a Japanese pharmaceutical company) for the promotion of Benicar (a drug used in the treatment of high blood pressure) in the United States.[1] Contract revenue accounted for 5% and 6% of total revenues in 2007 and 2006, respectively.[2]

Interest Income and Other (3% of Revenue)

Fiscal 2008 saw 3% of Forest's revenue come from interest and other sources, as compared to 2.5% in 2007 and 3% in 2006.[2]

Drug 2006 Sales 2007 Sales 2008 Sales 2008 Drug Class Sub-Market Share
Lexapro$1.87 B$2.10 B$2.29 B17.50%
Namenda$503 M$669 M$830 M33.40%


Revenue Breakdown Graph

Forest Laboratories' Revenue by Source and a Breakdown of Sales for Fiscal 2008.  (Click to enlarge.)
Forest Laboratories' Revenue by Source and a Breakdown of Sales for Fiscal 2008. (Click to enlarge.)

Key Trends and Forces

Forest Laboratories Gets 90% of its Sales From Only Two Drugs, the Patents for Both of Which Are Set to Expire Within Five Years

In the fiscal year ended March 31, 2008, 66% of Forest Laboratory's sales came from antidepressant drug Lexapro, while 24% of sales came from Alzheimer's treatment drug Namenda.[1] The patents on both of these drugs are set to expire within the next five years; Lexapro in March, 2012 and Namenda in September, 2013. [1] If Forest is to remain successful going forward, they will need to develop or license one or more new blockbuster products to make up for the inevitable sales losses to be suffered from the introduction of generics.

Products in Forest Laboratories' pipeline include:

  • Ceftaroline, an injectable antibiotic acquired through the aforementioned acquisition of Cerexa.[1] Phase III studies of ceftaroline for complicated skin and skin structure infections began in February of 2007.[1] In fiscal year 2008, these studies completed enrollment with results expected in the second half of calendar year 2008.[1] Additionally in fiscal 2008, enrollment began for Phase III studies with patients suffering from community acquired pneumonia, with results expected in calendar year 2009.[1]
  • Linaclotide, a product for the treatment of gastrointestinal disorders developed through a 50/50 co-development and marketing parntnership with Ironwood Pharmaceuticals, Inc.[1] In March of 2008, Forest announced positive top-line results from a series of Phase II(b) studies on linaclotide with patients suffering gastrointestinal disorders; the company anticipates initiating Phase III studies in the second half of calendar 2008.[1]
  • Aclidinium, a drug for treating respiratory diseases to which Forest has acquired exclusive United States marketing rights through a collaborative agreement with Laboratorios Almirall SA of Spain.[1] Phase II studies for the drug were positive and an international Phase III study is currently being conducted jointly by Forest and Almirall with top-line results expected in the second-half of calendar 2008.[1]

The Antidepressant Market is Populated with Numerous Products and Has Begun Slowing

Sales of Lexapro have grown steadily, increasing 9% from their last year's totals and, in fiscal 2008, accounting for 17.7% of total antidepressant prescriptions in the SSRI/SNRI (selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor) category.[5] However, the antidepressant market has slowed in the fiscal year that began April 1st 2008 while, concurrently, Lexapro has lost some market share to generics of (ironically enough) Forest Laboratory's own Celexa and other SSRI's.[6]

The Maturation of the Alzheimer's Drug Market Will Slow The Rate of Namenda's Sales Growth

Sales of Forest's Alzheimer's treatment drug Namenda have grown significantly, with 30% and 26% growth in fiscals 2007 and 2008, respectively, giving the drug 33.8% of total prescriptions in the Alzheimer's market.[5] This is due largely to its recent introduction (2003) and status as the first FDA approved drug for treatment of moderate-to-late stage Alzheimer's Disease.[1][4] While Forest Laboratories predicts that sales will continue to grow for the next several years,[5] analysts predict the maturation of the Alzheimer's drug market should continue to slow the rate of growth.[6]

Competition

Forest's relatively small size within the pharmaceutical industry makes it particularly susceptible to competition, lacking the financial resources to develop and sell a wide array of products, relying instead on the success of a few key drugs.[1] Some of Forest Laboratories' major competitors include:

  • Teva Pharmaceutical Industries (TEVA): The world's largest producer of generic drugs[7], Teva sells numerous generic versions of the branded drugs that Forest Laboratories produces and sells, most notably Cetalopram, the generic form of Forest's Celexa, a selective serotonin reuptake inhibitor and precursor to Lexapro.[8][9]
  • Pfizer (PFE): One of the worlds largest drug companies with a market cap more than ten times Forest Laboratories',[10][3] Pfizer develops, produces, and distributes hundreds of pharmaceutical products. These include (most notably from Forest's point of view) three different types of antidepressants (including SSRI Zoloft)[11] and Aricept, a drug for the treatment of Alzheimer's disease[12]
  • Eli Lilly and Company (LLY): Another major pharmaceutical company that develops, produces and distributes drugs including Prozac and Cymbalta for depression.[13] Their status as a producer of central nervous system drugs makes them a direct competitor of Forest's.
Company Total Revenues (most recent filing) R&D Expenditures (most recent filing) Net Income (most recent filing)
Forest Laboratories (FRX)$3.84 B$671 MM$968 MM
Pfizer (PFE)$48.42 B$8.10 B$8.14 B
Eli Lilly and Co (LLY)$18.63 B$3.49 B$2.95 B
Teva Pharmaceuticals (TFE)$2.82 B$198 MM$539 MM




References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 "Forest Laboratories Form 10-K For Fiscal Year 2008; Part I, Item 1 - Business"
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Consolidated Income Statement From Forest Laboratories Form 10-K For Fiscal Year 2008"
  3. 3.0 3.1 "Google Finance's Coverage of Forest Laboratories"
  4. 4.0 4.1 Morningstar Analyst Report of Forest Laboratories, 7/2008
  5. 5.0 5.1 5.2 "Forest Laboratories Form 10-K For Fiscal Year 2008; Part IV, Condition and Results of Operations"
  6. 6.0 6.1 The Value Line's Custom Report of Forest Laboratories, 7/2008
  7. "BioJerusalem entry on Teva Pharmaceutical Industries."
  8. "Notes to Consolidated Financial Statements from Forest Laboratories Form 10-K, Section IV"
  9. "Wikipedia entry on Celexa (citalopram)"
  10. "Google Finance's Coverage of Pfizer"
  11. "Pfizer's List of Products for the Treatment of Depression, August 2008"
  12. "Pfizer's List of Products for the Treatment of Alzheimer's Disease, August 2008"
  13. "Eli Lilly's Official Product List, August 2008"
Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki